JNJ · Forward model · Neuroscience
What has to happen in Neuroscience
Model as of
This page changes Neuroscience inside the complete JNJ model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.
Shares this vertical and portfolio case. Slider and horizon edits stay in your browser.
Neuroscience
Basis quarter$2.34B
Final quarter$3.35B
Implied CAGR+7%
Final revenue mix10%
SPRAVATO plus CAPLYTA (Intra-Cellular, closed April 2025) turned a flat franchise into a mid-teens grower; the 2025 Q2 step is acquisition, not organic.
Last four quarters
2025 Q3
$2.02B
Reported
2025 Q4
$2.12B
Reported
2026 Q1
$2.17B
Reported
2026 Q2
$2.34B
Reported
SPRAVATOCAPLYTAINVEGA SUSTENNA/TRINZACONCERTA (declining)Other neuroscience
Sequential growth
+2.6%/qtr
decaying toward +1.2%
2.6% a quarter against +13.9% year over year; the 2025 Q2 jump was the CAPLYTA deal, not run-rate.
Neuroscience
Latest: $3.35B (2031Q2E)
| Period | Value |
|---|---|
| 2023Q1 | $1.80B |
| 2023Q2 | $1.79B |
| 2023Q3 | $1.74B |
| 2023Q4 | $1.80B |
| 2024Q1 | $1.80B |
| 2024Q2 | $1.78B |
| 2024Q3 | $1.75B |
| 2024Q4 | $1.77B |
| 2025Q1 | $1.65B |
| 2025Q2 | $2.05B |
| 2025Q3 | $2.02B |
| 2025Q4 | $2.12B |
| 2026Q1 | $2.17B |
| 2026Q2 | $2.34B |
| 2026Q3E | $2.40B |
| 2026Q4E | $2.46B |
| 2027Q1E | $2.51B |
| 2027Q2E | $2.57B |
| 2027Q3E | $2.62B |
| 2027Q4E | $2.68B |
| 2028Q1E | $2.73B |
| 2028Q2E | $2.78B |
| 2028Q3E | $2.83B |
| 2028Q4E | $2.88B |
| 2029Q1E | $2.93B |
| 2029Q2E | $2.98B |
| 2029Q3E | $3.02B |
| 2029Q4E | $3.07B |
| 2030Q1E | $3.12B |
| 2030Q2E | $3.16B |
| 2030Q3E | $3.21B |
| 2030Q4E | $3.26B |
| 2031Q1E | $3.30B |
| 2031Q2E | $3.35B |
Assumptions & reasoning
- 2025 Q1 $1,647M to 2025 Q2 $2,051M is the Intra-Cellular and CAPLYTA acquisition, closed April 2025, not organic acceleration. Year-over-year comparisons become clean only from 2026 Q2.
- Left aseasonal: the Q1 window spread of 11.6% is larger than the whole 8.3% amplitude, because the acquisition step sits inside the sample. That is an acquisition date, not a calendar.